Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Optibrium Appoints Director of Computational Chemistry

Published: Tuesday, April 29, 2014
Last Updated: Tuesday, April 29, 2014
Bookmark and Share
Appointment of Dr Peter Hunt represents part of further growth across all areas of its business.

This success is built on a growing, global customer base for Optibrium’s flagship product StarDrop™ within the pharmaceutical industry and its adoption in other chemistry fields including agrochemicals and cosmetics. Optibrium has also recently extended its product portfolio with the introduction of Asteris™, an iPad app that enables researchers to rapidly evaluate new compound ideas when and where they want.

Reflecting the growth in the business, Optibrium has expanded its R&D and operational teams to further accelerate the rate of product innovation and support its rapidly growing customer base. This has required the company to extend its facilities by 50%, less than two years after its last office expansion.

As part of the expansion of the R&D team, Dr Peter Hunt has joined as Director of Computational Chemistry. Peter joins Optibrium from Novartis, where he was Group Leader, Computer Aided Drug Discovery (CADD). Peter has over 25 years of experience in drug discovery, both in industry and academic research, having previously been CADD Group Leader at Merck and the 3D Centre in Australia. Peter will provide leadership on research efforts relating to Optibrium’s software and the EU funded HeCaToS project, and his extensive drug discovery experience will further support users of Optibrium’s software platforms.

Peter commented, “I am delighted to be joining Optibrium and contributing to the development of the StarDrop product and the research into hepatic and cardiac toxicity estimation funded through the EU. Having been a user of StarDrop for several years, I have been impressed by the usability and intuitive nature of the software and I hope to build on this as we bring new features to StarDrop and Optibrium’s growing product portfolio.”

Dr Matthew Segall, Optibrium’s CEO, added “We are very happy to welcome Peter to our team, which has maintained an impressive rate of innovation over the last 5 years as we expanded our customer base worldwide. The continued growth of Optibrium is a result of the team’s hard work and together we look forward to developing new solutions that will help scientists to improve the efficiency and productivity of drug discovery.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Optibrium Appoints Head of North American Operations to Support Growing Demand
Appointment marks the opening of new office in Cambridge, MA.
Thursday, September 03, 2015
Optibrium and Certara Collaborate
Collaboration will see integration of Optibrium’s StarDrop and Certera’s D360 platform.
Tuesday, April 21, 2015
Optibrium and ChemAxon Collaborate
Interface between StarDrop and Plexus facilitates seamless access to both software platforms.
Wednesday, April 15, 2015
Optibrium and NextMove Software Announce Technology Collaboration
Automatic application of Matsy method for matched series analysis within StarDrop™ will guide compound optimization in drug discovery.
Friday, January 16, 2015
Optibrium Joins HeCaToS Project and Expands R&D Team
The Hepatic and Cardiac Toxicity Systems project is a major European project with the objective to efficiently investigate the health impact of compounds on the heart and liver.
Tuesday, October 08, 2013
Optibrium and AstraZeneca Sign Licensing Agreement
AstraZeneca’s researchers select StarDrop Software from Optibrium to guide successful drug discovery.
Tuesday, July 02, 2013
Optibrium and Digital Chemistry Announce Technology Collaboration
Integration of bioisostere database with automatic application and prioritisation will guide the identification of successful, novel, high quality compounds in drug discovery.
Friday, December 14, 2012
Optibrium Goes from Strength to Strength as Global Customer Base Continues to Grow
Company celebrates growth in all areas of the company as it enters its fourth year of business.
Friday, September 21, 2012
Optibrium and Cresset Announce Technology Collaboration
Technology exchange combines unique methods for design of novel, high quality compounds in drug discovery.
Thursday, January 05, 2012
Optibrium to Preview New In Silico Drug Discovery Platform at Molecular Med Tri-Conference 2011
The exclusive preview of StarDrop™ will be available on booth #501, at San Francisco’s Moscone North Convention Centre.
Thursday, February 17, 2011
Optibrium Showcases StarVue at ACS Spring 2010
Offering an Innovative Free Way to Explore Compound Data for Drug Discovery
Thursday, February 18, 2010
Optibrium Launches Online Community for Drug Optimisation
Optibrium today announces the launch of its online community. This provides a rich environment for users of its StarDrop software to interact and gain even more value from this unique platform to guide compound design and selection decisions in drug discovery.
Monday, November 23, 2009
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!